+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Research Training Programme (Fellowship)

European Charcot Foundation

This ECF programme has been developed to offer talented young researchers in the area of Multiple Sclerosis the opportunity to work in an excellent research institution to enhance her/his competences on specific fields in MS. This is a short-term programme (3 to 6 months) aimed at offering basic and clinical researchers the opportunity to benefit from training in a specific research methodology or techniques at a reputed and highly recognized Research Centre. Application from researchers of emerging countries with the aim of acquiring competences and expertise not currently available in or of clear value to their home country are particularly welcome. The exact duration of the training will be decided by the ECF Training Programme Selection Committee on a case-by-case basis, according to the candidate’s training needs and availability of the host MS Centre. The programme welcomes applicants from all regions. To apply, applicants should complete and submit the Candidate Application Form.

AI Based Application Success Predictor

1️⃣ Central Relevance to Progressive MS

ECF’s mission emphasizes deepening understanding and slowing/halting progression.

Priority themes:

Mechanisms of neurodegeneration

Oligodendrocyte biology & remyelination

Disability progression biomarkers

Chronic inflammation & glial interaction

Imaging or digital endpoints tracking progression

Translational concepts aimed at clinical change

Bottom line: Not general neuro, not relapse-only MS — must be tied to progression.

2️⃣ Translational Potential: From Mechanism → Patient Benefit

Even basic research must:

Define a path to human data

Address a clinical bottleneck in MS care

Include endpoints that predict real-world improvement

Concrete question reviewers ask:

“Will this help progressive MS patients within 5–10 years?”

3️⃣ Preliminary Data Validating Feasibility

Especially for:

Mechanistic/target-driven studies

Therapeutic or biomarker discovery programs

Evidence can include:

Early in vivo proof-of-concept

Human-derived cells or tissues

Pilot imaging or biofluid results

4️⃣ Strong Team + Strategic Collaborations

ECF encourages interaction with:

MS clinics and cohorts across Europe

Imaging centers, neuropathology units

Progressive MS Alliance–aligned teams

Advantage: Multidisciplinary consortia > isolated labs.

5️⃣ Use of Human-Relevant Models / Data

Progressive-MS patient biospecimens

Advanced MRI metrics

CSF/serum biomarkers

Computational models linked to clinical endpoints

Patient-derived iPSCs supporting mechanisms

Human translation is a weight-bearing scoring criterion.

6️⃣ Novel, High-Impact Hypothesis

ECF supports:

Innovative and daring mechanistic ideas

Unexplored pathways in progression biology

Remyelination or neuroprotection strategies

Incremental improvements are less competitive.

7️⃣ Clear, Realistic 2–3 Aim Design

Reviewer-friendly format:

Hypothesis-driven aim structure

Defined milestones and success criteria

Manageable timeline (typically ≤ 2–3 years)

Risk is fine — but risk without contingency planning is not.

8️⃣ Strong Communication & Engagement Track

ECF appreciates investigators who:

Disseminate findings at ECF scientific meetings

Contribute to the MS research community and guidelines

Can translate outputs to clinicians and patient orgs

Grants are not only about the science, but the ecosystem.

Specialties

Pathology

Physiology

Eligibility Requirements

- Candidates must be post graduate.

- Candidates with a specialty interest in pathology, pathogenesis/pathophysiology, epidemiology, diagnosis, monitoring and treatment/management or any other field of medicine that is related and important to MS are eligible.

- Candidates must be less than 40 years of age.

- The training should be focused in an area relevant to Multiple Sclerosis.

- Candidates and their mentors must affirm that there will be no language barriers that will impede the training experience.

Sponsor Details

Sponsor Institute/Organizations: European Charcot Foundation

Sponsor Type: Corporate/Non-Profit

Address: Louizalaan 367 1050 Brussels Belgium Off. RegNb. BE0547 995 164

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity